Definitive Surgical Resection

PROCEDURE4 trials

Sponsors

M.D. Anderson Cancer Center, Jonsson Comprehensive Cancer Center, Mayo Clinic, Yana Najjar

Conditions

Ewing SarcomaLeiomyosarcomaLocally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell CarcinomaMalignant Peripheral Nerve Sheath TumorMelanomaCutaneous Melanoma Resectable, MelanomaMyxofibrosarcomaNasal Cavity and Paranasal Sinus Poorly Differentiated CarcinomaPleomorphic Rhabdomyosarcoma

Phase 1

Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma

Active, not recruitingNCT04420975

Jonsson Comprehensive Cancer CenterLeiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor, Myxofibrosarcoma +27

Start: 2020-10-14End: 2028-01-31Updated: 2026-03-10

Phase 2

Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

TerminatedNCT00707473

M.D. Anderson Cancer CenterLocally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma, Sinonasal Undifferentiated Carcinoma +4

Start: 2008-06-16End: 2026-06-01Updated: 2026-07-17

Neoadjuvant RP2 + Nivolumab in Patients With Melanoma

Not yet recruitingNCT07862530

Yana NajjarMelanomaCutaneous Melanoma Resectable, Melanoma

Start: 2026-12-31End: 2033-12-31Target: 34Updated: 2026-10-07

Unknown Phase

Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial

RecruitingNCT07188532

Mayo ClinicEwing Sarcoma, Round Cell Sarcoma With EWSR1-non-ETS Fusion

Start: 2025-12-05End: 2033-08-25Target: 170Updated: 2026-10-06

Related Papers

Table S2 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results

2026-07-01

Phase II prospective trial of induction chemotherapy for advanced sinonasal squamous cell or poorly differentiated carcinoma.

Journal of Clinical Oncology2023-06-015 citations

Abstract CT221: A phase I study of intratumoral BO-112 and nivolumab for resectable soft tissue sarcoma

Cancer Research2021-07-013 citations